Motilal Oswal: Indian Pharma Market’s Growth Pauses In November After A Strong Performance In October
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian pharmaceutical market performance was muted in November 2020, registering 1% YoY growth versus 9.6% YoY in October 2020.
After a decent growth of 6.6% YoY in October 2020, growth in anti-Infective therapies were flat YoY in Nov-20.
Respiratory therapies continued their dismal performance, recording a sales decline of 6.9% YoY in Nov-20.
Cardiac/gastro/anti-diabetic therapies exhibited a growth of 8.7%/3.1%/1.9% YoY in Nov-20.
On a moving-annual-total basis, industry growth came in at 3% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.